Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver disease study aims to unlock secrets of weight loss surgery

NCT ID NCT04141592

Knowledge-focused Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares people with non-alcoholic fatty liver disease (NAFLD) to healthy controls to understand how the immune system, metabolism, and gut bacteria differ. Researchers will also track what happens to liver health in NAFLD patients who undergo weight loss surgery. The goal is to learn why some patients improve after surgery and identify markers that could guide future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bariatric surgery (weight loss surgery)
What this could lead to
If successful, this could reveal key biological pathways in NAFLD and show whether weight loss surgery can reverse liver damage.
What could go wrong
This is an observational study, not a treatment trial. Results may not lead to new therapies, and findings may not apply to all NAFLD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 153 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2019

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be identified from outpatient clinics of Bariatric, Gastroenterology, and Hepatology services at Homerton and King College Hospitals in addition to Gastroenterology outpatients from the Barts Health NHS Trust. Healthy control participants will be identified from patients undergoing outpatient assessment, gastroscopy or surgery for other non-malignant gastrointestinal disorders at hospital sites.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Confirmed non-alcoholic Fatty liver disease (diagnosed clinically, radiologically or histologically) * If diabetic, Diagnosed with Type 2 Diabetes Mellitus OR • Healthy Control: no diagnosis of any liver condition including NAFLD o NAFLD excluded by Fibroscan Controlled Attenuation Parameter (CAP) score of \<222 dB/m Exclusion Criteria: * Unwilling or unable to give informed consent * Type 1 Diabetes Mellitus * Other form of liver disease (other than NAFLD) o Viral hepatitis, Auto-immune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, haemochromatosis, Sarcoidosis, cystic fibrosis, sickle cell disease * Taking medication associated with liver dysfunction (except methotrexate) * Auto-immune disease which in the investigator's opinion may confound immune profiling * Concomitant immunosuppressive medications (except methotrexate, short course oral steroids or inhaled corticosteroids) * Currently pregnant * Any major organ transplant (excluding corneal or hair transplant) * Regular alcohol intake greater than 14 units a week for female participants and 21 units a week for male participants

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-alcoholic fatty liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-alcoholic fatty liver disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Homerton University Hospital Foundation Trust

    RECRUITING

    London, Greater London, E9 6SR, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.